Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Medical Case Reports
Published in: Journal of Medical Case Reports 1/2019

Open Access 01-12-2019 | Pituitary Adenoma | Case report

Focal segmental glomerulosclerosis in which urinary protein improved after surgical treatment for acromegaly: a case report

Authors: Arina Yamasaki, Daisuke Bito, Erina Eto, Keiichiro Matsumoto, Megumi Nakamura, Junji Miyazaki, Kenichi Matsumoto, Masanori Masuda, Daisuke Mori, Toru Yoshimura

Published in: Journal of Medical Case Reports | Issue 1/2019

Login to get access

Abstract

Background

Focal segmental glomerulosclerosis is characterized by partial (segmental) sclerotic lesions in some glomeruli (focal). Primary focal segmental glomerulosclerosis is generally considered resistant to steroid therapy. However, acromegaly is a disease that causes peculiar facial features, body types, and metabolic abnormalities due to the excessive secretion of growth hormone by a pituitary adenoma. Growth hormone has been reported to be involved in glomerular cell growth, mesangial proliferation, and glomerulosclerosis in the kidney.

Case presentation

We report a case of a Japanese patient with focal segmental glomerulosclerosis in whom decreased urinary protein was observed after surgical treatment for acromegaly.

Conclusion

The patient’s urinary protein improved as the concentration of growth hormone/insulin-like growth factor 1 decreased.
Literature
1.
Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet. 1998;352:1455–61.CrossRef
2.
Swearingen B, Barker FGII, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83:3419–26.PubMed
3.
Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–52.CrossRef
4.
Hoogenberg K, Sluiter WJ, Dullaart RP. Effect of growth hormone and insulin-like growth factor I on urinary albumin excretion: studies in acromegaly and growth hormone deficiency. Acta Endocrinol. 1993;129:151–7.CrossRef
5.
Hiroshi S. Focal segmental glomerulosclerosis [in Japanese]. Nihon Naika Gakkai Zasshi. 2013;102:1114–20.CrossRef
6.
Kent DM, Jafar TH, Hayward RA, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol. 2007;18:1959–65.CrossRef
7.
Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49:19–26.CrossRef
8.
Daisuke S, Masao T. IGF-I (insulin-like growth factor-I). Nippon Rinsho. 2006;64(Suppl 2):308-11. (in Japanese).
9.
Oh Y. The insulin-like growth factor system in chronic kidney disease: pathophysiology and therapeutic opportunities. Kidney Res Clin Pract. 2012;31:26–37.CrossRef
10.
Doi T, Striker LJ, Gibson CC, et al. Glomerular lesions in mice transgenic for growth hormone and insulinlike growth factor-I: I. Relationship between increased glomerular size and mesangial sclerosis. Am J Pathol. 1990;137:541–52.PubMedPubMedCentral
11.
Flyvbjerg A, Frystyk J, Osterby R, Orskov H. Kidney IGF-I and renal hypertrophy in GH-deficient diabetic dwarf rats. Am J Phys. 1992;262:E956–62.CrossRef
12.
Bellush LL, Doublier S, Holland AN, et al. Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology. 2000;141:163–8.CrossRef
13.
Flyvbjerg A, Frystyk J, Thorlacius-Ussing O, Orskov H. Somatostatin analogue administration prevents increase in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats. Diabetologia. 1989;32:261–5.CrossRef
14.
Flyvbjerg A, Marshall SM, Frystyk J, et al. Octreotide administration in diabetic rats: effects on renal hypertrophy and urinary albumin excretion. Kidney Int. 1992;41:805–12.CrossRef
15.
Gronbaek H, Nielsen B, Frystyk J, et al. Effect of lanreotide on local kidney IGF-I and renal growth in experimental diabetes in the rat. Exp Nephrol. 1996;4:295–303.PubMed
16.
Igarashi K, Nakazawa A, Tani N, et al. Effect of a somatostatin analogue (SMS 201-995) on renal function and urinary protein excretion in diabetic rats. J Diabet Complicat. 1991;5:181–3.CrossRef
17.
Landau D, Segev Y, Afargan M, et al. A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse. Kidney Int. 2001;60:505–12.CrossRef
18.
Cummings EA, Sochett EB, Dekker MG, et al. Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes. Diabetes. 1998;47:1341–6.CrossRef
19.
Blankestijn PJ, Derkx FH, Birkenhager JC, et al. Glomerular hyperfiltration in insulin-dependent diabetes mellitus is correlated with enhanced growth hormone secretion. J Clin Endocrinol Metab. 1993;77:498–502.PubMed
20.
Serri O, Beauregard H, Brazeau P, et al. Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. JAMA. 1991;265:888–92.CrossRef
21.
Clemens A, Klevesath MS, Hofmann M, et al. Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus. Metabolism. 1999;48:1236–40.CrossRef
22.
Falkheden T, Sjogren B. Extracellular fluid volume and renal function in pituitary insufficiency and acromegaly. Acta Endocrinol. 1964;46:80–6.CrossRef
23.
Falkheden T, Wickbom I. Renal function and kidney size following hypophysectomy in man. Acta Endocrinol. 1965;48:348–54.CrossRef
24.
Sonksen PH, Russell-Jones D, Jones RH. Growth hormone and diabetes mellitus: a review of sixty-three years of medical research and a glimpse into the future? Horm Res. 1993;40:68–79.CrossRef
25.
Hiromichi Y, Bunshiro A, Naokatsu S, et al. Effect of pituitary microsurgery on acromegaly complicated nephrotic syndrome with focal segmental glomerulosclerosis: report of a rare clinical case. Am J Kidney Dis. 1999;33(6):1158–63.CrossRef
Metadata
Title
Focal segmental glomerulosclerosis in which urinary protein improved after surgical treatment for acromegaly: a case report
Authors
Arina Yamasaki
Daisuke Bito
Erina Eto
Keiichiro Matsumoto
Megumi Nakamura
Junji Miyazaki
Kenichi Matsumoto
Masanori Masuda
Daisuke Mori
Toru Yoshimura
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2019
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-019-2228-z

Other articles of this Issue 1/2019

Journal of Medical Case Reports 1/2019 Go to the issue

Case report

Crohn’s disease in a developing African mission hospital: a case report

Case report

Iatrogenic intralenticular broken steroid implant: a case report

Case report

Multiple cutaneous metastasis of synchronous urothelial carcinoma of the bladder and the renal pelvis: a case report

Case report

Neoadjuvant chemotherapy for primary sarcoma of the breast: a case report

Case report

A giant apocrine hidrocystoma associated with elevated serum carcinoembryonic antigen levels: a case report

Case report

Bleb wall recession technique to repair giant bleb formation after Ahmed Glaucoma Valve implantation: a case report